These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 35371622)

  • 1. STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer.
    Da Y; Liu Y; Hu Y; Liu W; Ma J; Lu N; Zhang C; Zhang C
    Oncoimmunology; 2022; 11(1):2054105. PubMed ID: 35371622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response.
    Marcus A; Mao AJ; Lensink-Vasan M; Wang L; Vance RE; Raulet DH
    Immunity; 2018 Oct; 49(4):754-763.e4. PubMed ID: 30332631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zebularine elevates STING expression and enhances cGAMP cancer immunotherapy in mice.
    Lai J; Fu Y; Tian S; Huang S; Luo X; Lin L; Zhang X; Wang H; Lin Z; Zhao H; Lin S; Zhao J; Xu S; Li D; Cai S; Dong L; Qian J; Liang J; Li Q; Zhang Y; Fan J; Balderas R; Chen Q
    Mol Ther; 2021 May; 29(5):1758-1771. PubMed ID: 33571681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microparticle Delivery of a STING Agonist Enables Indirect Activation of NK Cells by Antigen-Presenting Cells.
    Watkins-Schulz R; Batty CJ; Stiepel RT; Schmidt ME; Sandor AM; Chou WC; Ainslie KM; Bachelder EM; Ting JP
    Mol Pharm; 2022 Sep; 19(9):3125-3138. PubMed ID: 35913984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of a STING Agonist Using Lipid Nanoparticles Inhibits Pancreatic Cancer Growth.
    Shaji SG; Patel P; Mamani UF; Guo Y; Koirala S; Lin CY; Alahmari M; Omoscharka E; Cheng K
    Int J Nanomedicine; 2024; 19():8769-8778. PubMed ID: 39220196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8
    Watkins-Schulz R; Tiet P; Gallovic MD; Junkins RD; Batty C; Bachelder EM; Ainslie KM; Ting JPY
    Biomaterials; 2019 Jun; 205():94-105. PubMed ID: 30909112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.
    Cheng N; Watkins-Schulz R; Junkins RD; David CN; Johnson BM; Montgomery SA; Peine KJ; Darr DB; Yuan H; McKinnon KP; Liu Q; Miao L; Huang L; Bachelder EM; Ainslie KM; Ting JP
    JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response.
    Li T; Cheng H; Yuan H; Xu Q; Shu C; Zhang Y; Xu P; Tan J; Rui Y; Li P; Tan X
    Sci Rep; 2016 Jan; 6():19049. PubMed ID: 26754564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STING-induced regulatory B cells compromise NK function in cancer immunity.
    Li S; Mirlekar B; Johnson BM; Brickey WJ; Wrobel JA; Yang N; Song D; Entwistle S; Tan X; Deng M; Cui Y; Li W; Vincent BG; Gale M; Pylayeva-Gupta Y; Ting JP
    Nature; 2022 Oct; 610(7931):373-380. PubMed ID: 36198789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment.
    Nagata M; Kosaka A; Yajima Y; Yasuda S; Ohara M; Ohara K; Harabuchi S; Hayashi R; Funakoshi H; Ueda J; Kumai T; Nagato T; Oikawa K; Harabuchi Y; Esteban C; Ohkuri T; Kobayashi H
    Cancer Immunol Immunother; 2021 Aug; 70(8):2301-2312. PubMed ID: 33507344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the cGAS-cGAMP-STING Activity of Cancer Cells.
    Pépin G; Gantier MP
    Methods Mol Biol; 2018; 1725():257-266. PubMed ID: 29322423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of STING agonist with anti-vascular RGD-(KLAKLAK)
    Czapla J; Drzyzga A; Ciepła J; Matuszczak S; Jarosz-Biej M; Pilny E; Cichoń T; Smolarczyk R
    Cancer Immunol Immunother; 2024 Jun; 73(8):148. PubMed ID: 38832958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.
    Temizoz B; Kuroda E; Ohata K; Jounai N; Ozasa K; Kobiyama K; Aoshi T; Ishii KJ
    Eur J Immunol; 2015 Apr; 45(4):1159-69. PubMed ID: 25529558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site.
    Ohkuri T; Kosaka A; Ishibashi K; Kumai T; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Celis E; Kobayashi H
    Cancer Immunol Immunother; 2017 Jun; 66(6):705-716. PubMed ID: 28243692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic GMP-AMP promotes the acute phase response and protects against Escherichia coli infection in mice.
    Yu Y; Guo H; Jiang W; Zhang C; Xing C; Chen D; Xu C; Su L
    Biochem Pharmacol; 2021 Jun; 188():114541. PubMed ID: 33812857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytosolic Delivery of Thiolated Mn-cGAMP Nanovaccine to Enhance the Antitumor Immune Responses.
    Chen C; Tong Y; Zheng Y; Shi Y; Chen Z; Li J; Liu X; Zhang D; Yang H
    Small; 2021 Apr; 17(17):e2006970. PubMed ID: 33719177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of Tumor-Cell STING Primes NK-Cell Therapy.
    Knelson EH; Ivanova EV; Tarannum M; Campisi M; Lizotte PH; Booker MA; Ozgenc I; Noureddine M; Meisenheimer B; Chen M; Piel B; Spicer N; Obua B; Messier CM; Shannon E; Mahadevan NR; Tani T; Schol PJ; Lee-Hassett AM; Zlota A; Vo HV; Ha M; Bertram AA; Han S; Thai TC; Gustafson CE; Venugopal K; Haggerty TJ; Albertson TP; Hartley AV; Eser PO; Li ZH; Cañadas I; Vivero M; De Rienzo A; Richards WG; Abu-Yousif AO; Appleman VA; Gregory RC; Parent A; Lineberry N; Smith EL; Jänne PA; Miret JJ; Tolstorukov MY; Romee R; Paweletz CP; Bueno R; Barbie DA
    Cancer Immunol Res; 2022 Aug; 10(8):947-961. PubMed ID: 35678717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LL-37 transports immunoreactive cGAMP to activate STING signaling and enhance interferon-mediated host antiviral immunity.
    Wei X; Zhang L; Yang Y; Hou Y; Xu Y; Wang Z; Su H; Han F; Han J; Liu P; Hu S; Koci MD; Sun X; Zhang C
    Cell Rep; 2022 May; 39(9):110880. PubMed ID: 35649354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2',3'-Cyclic GMP-AMP Dinucleotides for STING-Mediated Immune Modulation: Principles, Immunotherapeutic Potential, and Synthesis.
    Shang M; Lu K; Guan W; Cao S; Ren M; Zhou C
    ChemMedChem; 2022 Jan; 17(2):e202100671. PubMed ID: 34807508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-assembled cGAMP-STINGΔTM signaling complex as a bioinspired platform for cGAMP delivery.
    He Y; Hong C; Yan EZ; Fletcher SJ; Zhu G; Yang M; Li Y; Sun X; Irvine DJ; Li J; Hammond PT
    Sci Adv; 2020 Jun; 6(24):eaba7589. PubMed ID: 32582856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.